This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comparative Study

. 1994 Nov;12(11):2515-6.

doi: 10.1200/JCO.1994.12.11.2515.

Tamoxifen versus medroxyprogesterone acetate for metastatic breast cancer

PMID: 7964968
DOI: 10.1200/JCO.1994.12.11.2515

Comparative Study

Tamoxifen versus medroxyprogesterone acetate for metastatic breast cancer

C D Atkins. J Clin Oncol. 1994 Nov.

. 1994 Nov;12(11):2515-6.

doi: 10.1200/JCO.1994.12.11.2515.

Author

PMID: 7964968
DOI: 10.1200/JCO.1994.12.11.2515

No abstract available

PubMed Disclaimer

Comment on

Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
Muss HB, Case LD, Atkins JN, Bearden JD 3rd, Cooper MR, Cruz JM, Jackson DV Jr, O'Rourke MA, Pavy MD, Powell BL, et al. Muss HB, et al. J Clin Oncol. 1994 Aug;12(8):1630-8. doi: 10.1200/JCO.1994.12.8.1630. J Clin Oncol. 1994. PMID: 8040675 Clinical Trial.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information